Use of Dabigatran for Periprocedural Anticoagulation in Patients Undergoing Catheter Ablation for Atrial Fibrillation
- 1 June 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Arrhythmia and Electrophysiology
- Vol. 6 (3), 460-466
- https://doi.org/10.1161/circep.113.000320
Abstract
Background—: Pulmonary vein isolation (PVI) for atrial fibrillation is associated with a transient increased risk of thromboembolic and hemorrhagic events. We hypothesized that dabigatran can be safely used as an alternative to continuous warfarin for the periprocedural anticoagulation in PVI. Methods and Results—: A total of 999 consecutive patients undergoing PVI were included; 376 patients were on dabigatran (150 mg), and 623 patients were on warfarin with therapeutic international normalized ratio. Dabigatran was held 1 to 2 doses before PVI and restarted at the conclusion of the procedure or as soon as patients were transferred to the nursing floor. Propensity score matching was applied to generate a cohort of 344 patients in each group with balanced baseline data. Total hemorrhagic and thromboembolic complications were similar in both groups, before (3.2% versus 3.9%; P =0.59) and after (3.2% versus 4.1%; P =0.53) matching. Major hemorrhage occurred in 1.1% versus 1.6% ( P =0.48) before and 1.2% versus 1.5% ( P =0.74) after matching in the dabigatran versus warfarin group, respectively. A single thromboembolic event occurred in each of the dabigatran and warfarin groups. Despite higher doses of intraprocedural heparin, the mean activated clotting time was significantly lower in patients who held dabigatran for 1 or 2 doses than those on warfarin. Conclusions—: Our study found no evidence to suggest a higher risk of thromboembolic or hemorrhagic complications with use of dabigatran for periprocedural anticoagulation in patients undergoing PVI compared with uninterrupted warfarin therapy.Keywords
This publication has 18 references indexed in Scilit:
- 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial DesignHeart Rhythm, 2012
- Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial FibrillationJournal of the American College of Cardiology, 2012
- How to do circular mapping catheter-guided pulmonary vein antrum isolation: The Cleveland Clinic approachHeart Rhythm, 2006
- Radiofrequency Ablation vs Antiarrhythmic Drugs as First-line Treatment of Symptomatic Atrial FibrillationJAMA, 2005
- Increased Intensity of Anticoagulation May Reduce Risk of Thrombus During Atrial Fibrillation Ablation Procedures in Patients with Spontaneous Echo ContrastJournal of Cardiovascular Electrophysiology, 2005
- Effects and non‐effects of paired identical observations in comparing proportions with binary matched‐pairs dataStatistics in Medicine, 2003
- Cerebrovascular complication associated with pulmonary vein ablation.Journal of Cardiovascular Electrophysiology, 2002
- Validating recommendations for coronary angiography following acute myocardial infarction in the elderlyJournal of Clinical Epidemiology, 2001
- Electrophysiological End Point for Catheter Ablation of Atrial Fibrillation Initiated From Multiple Pulmonary Venous FociCirculation, 2000
- Does Radiofrequency Ablation Induce a Prethrombotic State? Analysis of Coagulation System Activation and Comparison to Electrophysiologic StudyJournal of Cardiovascular Electrophysiology, 1998